000			02022 a2200601 4500
005			20250515073107.0
264		0	_c20071026
008			200710s 0 0 eng d
022			_a1120-009X
024	7		_a10.1179/joc.2007.19.3.315 _2doi
040			_aNLM _beng _cNLM
100	1		_aGalimberti, S
245	0	0	_aThe efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms. _h[electronic resource]
260			_bJournal of chemotherapy (Florence, Italy) _cJun 2007
300			_a315-21 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Murine-Derived
650	0	4	_aAntigens, CD _xgenetics
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aCyclophosphamide _xtherapeutic use
650	0	4	_aDexamethasone _xtherapeutic use
650	0	4	_aDisease-Free Survival
650	0	4	_aDoxorubicin _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLymphoma, Mantle-Cell _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPolymerase Chain Reaction
650	0	4	_aPolymorphism, Genetic
650	0	4	_aProspective Studies
650	0	4	_aReceptors, IgG _xgenetics
650	0	4	_aRituximab
650	0	4	_aVincristine _xtherapeutic use
700	1		_aPalumbo, G A
700	1		_aCaracciolo, F
700	1		_aBenedetti, E
700	1		_aPelosini, M
700	1		_aBrizzi, S
700	1		_aCiabatti, E
700	1		_aFazzi, R
700	1		_aStelitano, C
700	1		_aQuintana, G
700	1		_aConte, E
700	1		_aTibullo, D
700	1		_aDi Raimondo, F
700	1		_aPetrini, M
773	0		_tJournal of chemotherapy (Florence, Italy) _gvol. 19 _gno. 3 _gp. 315-21
856	4	0	_uhttps://doi.org/10.1179/joc.2007.19.3.315 _zAvailable from publisher's website
999			_c17131703 _d17131703